Company: ORIB
Filing Date: 2025-07-08
Form Type: 10-K
Source: 0001683168-25-004973
Chunk: 50

Company: Orion Bliss Corp.
Filing Date: 2025-07-08
Form: 10-K
Item: Item 1C
Chunk 50
---
 flat 21% rate, effective January 1, 2018.

The reconciliation of
income tax benefit (expenses) at the U.S. statutory rate at 21% for the period ended as follows:

    Schedule of income tax expense 
    April 30, 2025  
    April 30, 2024 

    Tax benefit (expenses) at U.S. statutory rate 
    $(3,088) 
    $(10,995)
  
    Change in valuation allowance 
     3,088  
     10,995 
  
    Tax benefit (expenses), net 
    $–  
    $– 

The tax effects of temporary differences that give rise to significant
portions of the net deferred tax assets are as follows:

    Schedule of deferred tax assets 
    April 30, 2025  
    April 30, 2024 

    Net operating loss 
    $(26,220) 
    $(23,132)
  
    Valuation allowance 
     26,220  
     23,132 
  
    Deferred tax assets, net 
    $–  
    $– 

The Company has accumulated approximately $124,856
of net operating losses (“NOL”) carried forward to offset future taxable income up to 20 years, if any, in future years which
begin to expire in year 2038. In assessing the realization of deferred tax assets, management considers whether it is more likely than
not that some portion or all of the deferred tax assets will be realized. The ultimate realization of deferred tax assets is dependent
upon the generation of future taxable income during the periods in which those temporary differences become deductible. Management considers
the scheduled reversal of deferred tax liabilities, projected future taxable income and tax planning strategies in making this assessment.
Based on the assessment, management has established a full valuation allowance against all of the deferred tax asset relating to NOLs
for every period because it is more likely than not that all of the deferred tax asset will not be realized.

NOTE 8 – SUBSEQUENT
EVENTS

In accordance with ASC
855-10 the Company has analyzed its operations subsequent to April 30, 2025 to the date these financial statements were issued, and has
determined that it does not have any material subsequent events to disclose in these financial statements.

The extent of the impact
of the coronavirus (“COVID-19”) outbreak on the financial performance of the Company will depend on future developments